Exsell Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -21.98%
- Profit Growth -14.33%
- Ebitda -3.23%
- Net Worth 29.63%
- Total Assets -14.59%
About Exsell Laboratories
Exsell Laboratories Private Limited (ELPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 March 2017 (Seven years and 11 months 8 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Santosh Singh and Arunkumar Singh serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U52520MH2017PTC291942
-
Company No.
291942
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Mar 2017
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Exsell Laboratories Private Limited offer?
Exsell Laboratories Private Limited offers a wide range of products and services, including Common Disease Medicines, Injectable Products, Anti Infective Drugs & Medicines, Malaria Medicine, Antiviral Drugs.
Who are the key members and board of directors at Exsell Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Singh
|
Director | 03-Mar-2017 | Current |
|
Arunkumar Singh
|
Director | 03-Mar-2017 | Current |
Financial Performance of Exsell Laboratories.
Exsell Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 21.98% decrease. The company also saw a substantial fall in profitability, with a 14.33% decrease in profit. The company's net worth Soared by an impressive increase of 29.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Exsell Laboratories?
In 2023, Exsell Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Exsell Laboratories?
Unlock and access historical data on people associated with Exsell Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Exsell Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Exsell Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.